

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ESSEX BIO-TECHNOLOGY LIMITED**

## **億勝生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1061)**

### **INSIDE INFORMATION APPROVAL TO COMMERCIALISE PRESERVATIVE-FREE SINGLE-DOSE BEIFUSHU EYE DROPS IN THE PRC**

This announcement is made by Essex Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company is pleased to announce that 珠海億勝生物製藥有限公司 (Zhuhai Essex Bio-Pharmaceutical Company Limited\*), an indirect wholly-owned subsidiary of the Company, has obtained an approval from 國家藥品監督管理局 (National Medical Products Administration) for the registration and commercialisation of the preservative-free single-dose Beifushu Eye Drops (貝復舒滴眼液) (the “**Approved Product**”) in the People’s Republic of China (the “**PRC**”), which for the purpose of this announcement, excludes the Hong Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan.

The Approved Product is a preservative-free single-dose Beifushu eye drops product, and is used to treat corneal epithelial defect, punctate keratopathy, recurring superficial punctate keratopathy, dry eye syndrome, bullous keratitis, corneal abrasion, etc.

The Approved Product is expected to be launched in the market soon. The Board believes that the Approved Product will enhance the choice of patients on the range of Beifushu series products for the best treatment outcome. The addition of the Approved Product will strengthen the competitiveness and leadership position of the Group in the growth factor formulated ophthalmic drugs.

On behalf of the Board  
**Essex Bio-Technology Limited**  
**Ngiam Mia Je Patrick**  
*Chairman*

Hong Kong, 27 December 2019

*Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou and Mr. Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.*

\* *For identification purpose only*